- Home
- TFX vs RYTM Comparison
TFX vs RYTM Comparison
Compare TFX & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFX
- RYTM
- Stock Information
- Founded
- TFX 1943
- RYTM 2008
- Country
- TFX United States
- RYTM United States
- Employees
- TFX N/A
- RYTM N/A
- Industry
- TFX Medical/Dental Instruments
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- TFX Health Care
- RYTM Health Care
- Exchange
- TFX Nasdaq
- RYTM Nasdaq
- Market Cap
- TFX 5.1B
- RYTM 5.9B
- IPO Year
- TFX N/A
- RYTM 2017
- Fundamental
- Price
- TFX $120.70
- RYTM $97.61
- Analyst Decision
- TFX Hold
- RYTM Strong Buy
- Analyst Count
- TFX 9
- RYTM 13
- Target Price
- TFX $141.57
- RYTM $101.92
- AVG Volume (30 Days)
- TFX 549.9K
- RYTM 578.8K
- Earning Date
- TFX 07-31-2025
- RYTM 08-05-2025
- Dividend Yield
- TFX 1.12%
- RYTM N/A
- EPS Growth
- TFX N/A
- RYTM N/A
- EPS
- TFX 4.18
- RYTM N/A
- Revenue
- TFX $3,041,342,000.00
- RYTM $156,287,000.00
- Revenue This Year
- TFX $3.50
- RYTM $37.86
- Revenue Next Year
- TFX $5.33
- RYTM $72.72
- P/E Ratio
- TFX $29.10
- RYTM N/A
- Revenue Growth
- TFX 1.11
- RYTM 53.55
- 52 Week Low
- TFX $108.90
- RYTM $43.57
- 52 Week High
- TFX $249.91
- RYTM $99.04
- Technical
- Relative Strength Index (RSI)
- TFX 55.48
- RYTM 73.48
- Support Level
- TFX $115.85
- RYTM $95.30
- Resistance Level
- TFX $123.09
- RYTM $99.04
- Average True Range (ATR)
- TFX 3.47
- RYTM 3.21
- MACD
- TFX 0.90
- RYTM 0.20
- Stochastic Oscillator
- TFX 73.99
- RYTM 90.50
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.